Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Bloom Burton
Stifel Nicolaus Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Echelon Wealth Partners Sticks to Their Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Stifel Nicolaus
Medexus Pharmaceuticals Inc (MDP) Gets a Buy Rating From Echelon Wealth Partners
Medexus Pharmaceuticals Inc (MDP) Gets a Buy Rating From Echelon Wealth Partners
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Echelon Wealth Partners
Medexus Pharmaceuticals Inc Price Target Cut to C$2.00/Share From C$4.50 by Raymond James